The immunotoxic effects of chemicals are varied and markedly different depending on the underlying pathogenesis, namely, direct immunotoxicity (including immunosuppression, immunodepression, and immunostimulation), hypersensitivity, and autoimmunity. A large number of immunological endpoints and functional assays have been proposed for use as biomarkers of immunotoxicity, but they often lack sensitivity or are poorly standardized, so that their relevance in assessing immunotoxic effects in humans is at best ill established. Examining sentinel immunopathological events in individuals with a defined history of chemical exposure is another approach, presumably more cost-effective at the present time. A multicenter collaboration is mandated, however, because these events are rare. We expect that progress in new technologies, e.g., molecular biology, will provide the sensitive and reliable biomarkers of immunotoxicity that are currently lacking.
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Indexing Terms: immunotoxicity/biomarkers/sentinel events
During the past two decades, evidence has accumulated that the immune system is a possible target organ of toxicity after exposure to a wide array of pharmaceutical products, as well as to industrial and environmental chemicals (1-3). Experimental studies on the immunotoxicity of many substances essentially in rodents have been published
(1), but until recently researchers paid only limited attention to immunotoxic effectsin humans (2, 3). Nevertheless, as exemplified by two recent panels ofexperts (4, 5), the assessment of immunotoxic effects in humans is becoming a timely issue. In particular, the relevance of identifying autoantibodies in asymptomatic patients is unknown. 
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